Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

1.

Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents.

Varley CK, McClellan J.

JAMA. 2009 Oct 28;302(16):1811-2. doi: 10.1001/jama.2009.1558. No abstract available.

PMID:
19861677
[PubMed - indexed for MEDLINE]
2.

Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Stigler KA, Potenza MN, Posey DJ, McDougle CJ.

Paediatr Drugs. 2004;6(1):33-44. Review.

PMID:
14969568
[PubMed - indexed for MEDLINE]
3.

Risks from antipsychotic medications in children and adolescents.

Lewin AB, Storch EA, Storch HD.

JAMA. 2010 Feb 24;303(8):729-30; author reply 730-1. doi: 10.1001/jama.2010.132. No abstract available.

PMID:
20179278
[PubMed - indexed for MEDLINE]
4.

Risks from antipsychotic medications in children and adolescents.

Mangurian C, Fuentes-Afflick E, Newcomer JW.

JAMA. 2010 Feb 24;303(8):729; author reply 730. doi: 10.1001/jama.2010.131. No abstract available.

PMID:
20179279
[PubMed - indexed for MEDLINE]
5.

The effect of atypical antipsychotic agents on prolactin levels in children and adolescents.

Pappagallo M, Silva R.

J Child Adolesc Psychopharmacol. 2004 Fall;14(3):359-71. Review.

PMID:
15650493
[PubMed - indexed for MEDLINE]
6.

Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?

Vieweg WV, Sood AB, Pandurangi A, Silverman JJ.

Acta Psychiatr Scand. 2005 Mar;111(3):177-84.

PMID:
15701101
[PubMed - indexed for MEDLINE]
7.

Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings.

Rani FA, Byrne PJ, Murray ML, Carter P, Wong IC.

Drug Saf. 2009;32(4):325-33. doi: 10.2165/00002018-200932040-00006.

PMID:
19388723
[PubMed - indexed for MEDLINE]
8.

Adverse events in children and adolescents treated with antipsychotic medications.

Jerrell JM, McIntyre RS.

Hum Psychopharmacol. 2008 Jun;23(4):283-90. doi: 10.1002/hup.932.

PMID:
18302312
[PubMed - indexed for MEDLINE]
9.

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.

Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA.

Am J Psychiatry. 2006 Dec;163(12):2072-9.

PMID:
17151157
[PubMed - indexed for MEDLINE]
10.

Risperidone-associated weight gain in children and adolescents: a retrospective chart review.

Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF.

J Child Adolesc Psychopharmacol. 2000 Winter;10(4):259-68.

PMID:
11191686
[PubMed - indexed for MEDLINE]
11.

Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.

Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A.

J Neural Transm. 2007 Feb;114(2):273-80. Epub 2006 Nov 17.

PMID:
17109073
[PubMed - indexed for MEDLINE]
12.

Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Toren P, Ratner S, Laor N, Weizman A.

Drug Saf. 2004;27(14):1135-56. Review.

PMID:
15554747
[PubMed - indexed for MEDLINE]
13.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Newcomer JW.

CNS Drugs. 2005;19 Suppl 1:1-93. Review.

PMID:
15998156
[PubMed - indexed for MEDLINE]
14.

Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.

Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A.

J Neural Transm. 2008 Nov;115(11):1599-608. doi: 10.1007/s00702-008-0105-9. Epub 2008 Sep 9.

PMID:
18779922
[PubMed - indexed for MEDLINE]
15.

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.

Russell JM, Mackell JA.

CNS Drugs. 2001;15(7):537-51. Review.

PMID:
11510624
[PubMed - indexed for MEDLINE]
16.

The implications of weight changes with antipsychotic treatment.

Sussman N.

J Clin Psychopharmacol. 2003 Jun;23(3 Suppl 1):S21-6. Review.

PMID:
12832946
[PubMed - indexed for MEDLINE]
17.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
[PubMed - indexed for MEDLINE]
18.

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.

Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM.

J Child Adolesc Psychopharmacol. 1998;8(3):151-9.

PMID:
9853689
[PubMed - indexed for MEDLINE]
19.

No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.

Rondanelli M, Sarra S, Antoniello N, Mansi V, Govoni S, Falvo F, Solerte SB, Ferrari E.

Minerva Med. 2006 Apr;97(2):147-51.

PMID:
16760853
[PubMed - indexed for MEDLINE]
20.

Risperidone-associated steatohepatitis and excessive weight-gain.

Holtmann M, Kopf D, Mayer M, Bechtinger E, Schmidt MH.

Pharmacopsychiatry. 2003 Sep;36(5):206-7.

PMID:
14571356
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk